Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Judith Trotman, FRACP, Christian Buske, MD, Alessandra Tedeschi, MD, Jeffrey V. Matous, MD, David MacDonald, MD, Constantine Tam, MBBS, Olivier Tournilhac, MD PhD, Shuo Ma, MD PhD, Steven P. Treon, MD PhD, Albert Oriol, Jerry Ping, PhD, Eva M. Briso, PhD, Israel Arango-Hisijara, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-133916

Published: 2020

Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134460

Published: 2020

Journal Articles

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Gloria G Chan, MS, Jiaji G Chen, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2823.

https://doi.org/10.1182/blood-2019-125069

Published: 2019

Journal Articles

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Toni Dubeau, NP, Gloria G Chan, MS, Jiaji Chen, BS, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2830.

https://doi.org/10.1182/blood-2019-122349

Published: 2019

Journal Articles

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Guang Yang, PhD, Jinhua Wang, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji G Chen, Amanda Kofides, Lian Xu, MS, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Jorge J. Castillo, MD, Sara J Buhrlage, PhD, Nathanael Gray, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 394.

https://doi.org/10.1182/blood-2019-130636

Published: 2019

Journal Articles

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Xia Liu, MD, Jiaji G Chen, Manit Munshi, MS, Lian Xu, MS, Amanda Kofides, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Kirsten Meid, MPH, Andrew Keezer, BS, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Guang Yang, PhD

Blood (2019) 134 (Supplement_1): 3778.

https://doi.org/10.1182/blood-2019-130885

Published: 2019

Journal Articles

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Ludmila Flores, Merav Leiba, MD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Steven P Treon, MD PhD FRCP, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3975.

https://doi.org/10.1182/blood-2019-130011

Published: 2019

Journal Articles

MYD88 Triggered SYK Activation Promotes BCR Cross-Talk, and Identifies SYK As a Novel Therapeutic Target of Mutated MYD88 Signaling

Manit Munshi, MS, Jiaji Chen, BS, Xia Liu, MD, Lian Xu, MS, Nickolas Tsakmaklis, BA, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Christopher Patterson, MAcc, Kirsten Meid, MPH, Joshua Gustine, MPH, Jorge J. Castillo, MD, Zachary R Hunter, PhD, Jinhua Wang, PhD, Sara J Buhrlage, PhD, Nathanael S. Gray, PhD, Steven P Treon, MD PhD FRCP, Guang Yang, PhD

Blood (2018) 132 (Supplement 1): 4116.

https://doi.org/10.1182/blood-2018-99-117372

Published: 2018

Journal Articles

Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies

Sara Morrow, BA, Dennis Dobrovolsky, PhD, Eric Wang, PhD, Radosław P. Nowak, PhD, Katherine Donovan, PhD, Tyler Faust, PhD, Guang Yang, PhD, Zhengnian Li, PhD, Eric Fischer, Steven P Treon, MD PhD FRCP, David M Weinstock, MD, Nathanael S. Gray, PhD

Blood (2018) 132 (Supplement 1): 263.

https://doi.org/10.1182/blood-2018-99-116895

Published: 2018

Journal Articles

Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia

Cristina Jimenez, PhD, Gloria G Chan, MS, Lian Xu, MS, Nickolas Tsakmaklis, Jiaji G Chen, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, MD, Xia Liu, MD, Manit Munshi, MS, Joshua Gustine, MPH, Guang Yang, PhD, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Zachary R Hunter, PhD

Blood (2018) 132 (Supplement 1): 1372.

https://doi.org/10.1182/blood-2018-99-118819

Published: 2018

Journal Articles

Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia

Gilad Itchaki, Toni Dubeau, NP, Andrew Keezer, BS, Kirsten Meid, MPH, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2018-99-114254

Published: 2018

Journal Articles

Deepening of Response after Completing Rituximab-Containing Primary Therapy in Patients with Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, MPH, Toni Dubeau, NP, Kirsten Meid, MPH, Andrew Keezer, BS, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2018-99-110675

Published: 2018

Journal Articles

Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, MPH, Kirsten Meid, MPH, Toni Dubeau, NP, Andrew Keezer, BS, John N. Allan, MD, Richard R. Furman, MD, Tanya Siddiqi, MD, Ranjana Advani, MD, Jessica Lam, Zachary R Hunter, PhD, Guang Yang, PhD, Lian Xu, MS, Matthew S Davids, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2018-99-112325

Published: 2018

Journal Articles

A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTK Cys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88

Guang Yang, PhD, Jinhua Wang, PhD, Li Tan, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji G Chen, Lian Xu, MS, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Zachary R Hunter, PhD, Christopher Patterson, MAcc, Jorge J. Castillo, MD, Sara J Buhrlage, PhD, Nathanael S. Gray, PhD, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 40.

https://doi.org/10.1182/blood-2018-99-119171

Published: 2018

Journal Articles

Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia

Blood (2018) 132 (Supplement 1): 150.

https://doi.org/10.1182/blood-2018-99-114324

Published: 2018

Journal Articles

Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, MPH, Andrew Keezer, BS, Kirsten Meid, MPH, Toni Dubeau, NP, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 1598.

https://doi.org/10.1182/blood-2018-99-111626

Published: 2018

Journal Articles

Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MYD88 and CXCR4 Genotype Status in WM

Zachary R Hunter, PhD, Gloria G Chan, MS, Cristina Jimenez, PhD, Nickolas Tsakmaklis, Lian Xu, MS, Jiaji G Chen, Maria Demos, Amanda Kofides, Manit Munshi, MS, Maria Luisa Guerrera, MD, Xia Liu, MD, Guang Yang, PhD, Jorge J. Castillo, MD, Ari M Melnick, MD, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2018-99-119828

Published: 2018

Journal Articles

Ibrutinib for the Treatment of Bing-Neel Syndrome

Gilad Itchaki, Jonas Paludo, MD, Maria Lia Palomba, MD, Marzia Varettoni, MD, Dipti Talaulikar, PhD FRACP, FRCPA, MBBS, Julio C. Chavez, MD, Christian Buske, MD, Alessandra Tedeschi, MD, David Simpson, MBChB, FRACP, FRCPA, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Samar Issa, FRACP, Stephen M. Ansell, MD PhD, Steven P Treon, MD PhD FRCP, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2018-99-116788

Published: 2018

Journal Articles

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

Amanda Kofides, Maria Demos, Nickolas Tsakmaklis, Lian Xu, MS, Xia Liu, MD, Christopher Patterson, Maria Luisa Guerrera, MD, Manit Munshi, MS, Guang Yang, PhD, Jiaji G Chen, Cristina Jimenez, PhD, Gloria G Chan, MS, Joshua Gustine, MPH, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Zachary R Hunter, PhD

Blood (2018) 132 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2018-99-119419

Published: 2018

Journal Articles

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Christian Buske, MD, Alessandra Tedeschi, MD, Judith Trotman, FRACP, Ramon García-Sanz, MD PhD, David MacDonald, MD, Véronique Leblond, MD PhD, Beatrice Mahe, MD, Charles Herbaux, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, M. Lia Palomba, MD, Jeffrey V Matous, MD, Chaim Shustik, MD, Eftathios Kastritis, MD, Steven P Treon, MD PhD FRCP, Chih-Jian Lih, PhD, Jianling Li, MS, Zeena Salman, BS, Thorsten Graef, MD PhD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 149.

https://doi.org/10.1182/blood-2018-99-111178

Published: 2018

NARROW

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

MYD88 Triggered SYK Activation Promotes BCR Cross-Talk, and Identifies SYK As a Novel Therapeutic Target of Mutated MYD88 Signaling

Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies

Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia

Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia

Deepening of Response after Completing Rituximab-Containing Primary Therapy in Patients with Waldenstrom Macroglobulinemia

Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia

A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTK Cys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88

Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia

Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia

Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MYD88 and CXCR4 Genotype Status in WM

Ibrutinib for the Treatment of Bing-Neel Syndrome

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only